234 related articles for article (PubMed ID: 31671444)
1. Impact of 13-Valent Pneumococcal Conjugate Vaccine on Pneumococcal Meningitis, Burkina Faso, 2016-2017.
Soeters HM; Kambiré D; Sawadogo G; Ouédraogo-Traoré R; Bicaba B; Medah I; Sangaré L; Ouédraogo AS; Ouangraoua S; Yaméogo I; Congo-Ouédraogo M; Ky Ba A; Aké F; Srinivasan V; Novak RT; McGee L; Whitney CG; Van Beneden C
J Infect Dis; 2019 Oct; 220(220 Suppl 4):S253-S262. PubMed ID: 31671444
[TBL] [Abstract][Full Text] [Related]
2. Early impact of 13-valent pneumococcal conjugate vaccine on pneumococcal meningitis-Burkina Faso, 2014-2015.
Kambiré D; Soeters HM; Ouédraogo-Traoré R; Medah I; Sangaré L; Yaméogo I; Sawadogo G; Ouédraogo AS; Ouangraoua S; McGee L; Srinivasan V; Aké F; Congo-Ouédraogo M; Ky Ba A; Whitney CG; Novak RT; Van Beneden C;
J Infect; 2018 Mar; 76(3):270-279. PubMed ID: 29253559
[TBL] [Abstract][Full Text] [Related]
3. Nationwide Trends in Bacterial Meningitis before the Introduction of 13-Valent Pneumococcal Conjugate Vaccine-Burkina Faso, 2011-2013.
Kambiré D; Soeters HM; Ouédraogo-Traoré R; Medah I; Sangare L; Yaméogo I; Sawadogo G; Ouédraogo AS; Hema-Ouangraoua S; McGee L; Srinivasan V; Aké F; Congo-Ouédraogo M; Sanou S; Ba AK; Novak RT; Van Beneden C;
PLoS One; 2016; 11(11):e0166384. PubMed ID: 27832151
[TBL] [Abstract][Full Text] [Related]
4. Incidence, seasonality, age distribution, and mortality of pneumococcal meningitis in Burkina Faso and Togo.
Traore Y; Tameklo TA; Njanpop-Lafourcade BM; Lourd M; Yaro S; Niamba D; Drabo A; Mueller JE; Koeck JL; Gessner BD
Clin Infect Dis; 2009 Mar; 48 Suppl 2():S181-9. PubMed ID: 19191614
[TBL] [Abstract][Full Text] [Related]
5. Can pneumococcal meningitis surveillance be used to assess the impact of pneumococcal conjugate vaccine on total invasive pneumococcal disease? A case-study from South Africa, 2005-2016.
Kleynhans J; Cohen C; McMorrow M; Tempia S; Crowther-Gibson P; Quan V; de Gouveia L; von Gottberg A;
Vaccine; 2019 Sep; 37(38):5724-5730. PubMed ID: 31076159
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of pneumococcal meningitis clusters in Burkina Faso and implications for potential reactive vaccination.
Soeters HM; Kambiré D; Sawadogo G; Ouédraogo-Traoré R; Bicaba B; Medah I; Sangaré L; Ouédraogo AS; Ouangraoua S; Yaméogo I; Congo-Ouédraogo M; Ky Ba A; Aké F; Velusamy S; McGee L; Van Beneden C; Whitney CG
Vaccine; 2020 Jul; 38(35):5726-5733. PubMed ID: 32591290
[TBL] [Abstract][Full Text] [Related]
7. Continued occurrence of serotype 1 pneumococcal meningitis in two regions located in the meningitis belt in Ghana five years after introduction of 13-valent pneumococcal conjugate vaccine.
Bozio CH; Abdul-Karim A; Abenyeri J; Abubakari B; Ofosu W; Zoya J; Ouattara M; Srinivasan V; Vuong JT; Opare D; Asiedu-Bekoe F; Lessa FC
PLoS One; 2018; 13(9):e0203205. PubMed ID: 30192772
[TBL] [Abstract][Full Text] [Related]
8. Characterization of pneumococcal meningitis before and after introduction of 13-valent pneumococcal conjugate vaccine in Niger, 2010-2018.
Ousmane S; Kobayashi M; Seidou I; Issaka B; Sharpley S; Farrar JL; Whitney CG; Ouattara M
Vaccine; 2020 May; 38(23):3922-3929. PubMed ID: 32327220
[TBL] [Abstract][Full Text] [Related]
9. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
[TBL] [Abstract][Full Text] [Related]
10. Pneumococcal Carriage in Burkina Faso After 13-Valent Pneumococcal Conjugate Vaccine Introduction: Results From 2 Cross-sectional Population-Based Surveys.
Kaboré L; Adebanjo T; Njanpop-Lafourcade BM; Ouangraoua S; Tarbangdo FT; Meda B; Velusamy S; Bicaba B; Aké F; McGee L; Yaro S; Betsem E; Gervaix A; Gessner BD; Whitney CG; Moïsi JC; Van Beneden CA
J Infect Dis; 2021 Sep; 224(12 Suppl 2):S258-S266. PubMed ID: 34469552
[TBL] [Abstract][Full Text] [Related]
11. Surveillance of impact of PCV-10 vaccine on pneumococcal meningitis in Mozambique, 2013 - 2015.
Nhantumbo AA; Weldegebriel G; Katsande R; de Gouveia L; Comé CE; Cuco AZ; Cantarelli VV; Dias C; Caierão J; Mathiu JM; Gudo ES
PLoS One; 2017; 12(6):e0177746. PubMed ID: 28604773
[TBL] [Abstract][Full Text] [Related]
12. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal meningitis in children.
Ruiz-Contreras J; Picazo J; Casado-Flores J; Baquero-Artigao F; Hernández-Sampelayo T; Otheo E; Méndez C; Del Amo M; Balseiro C;
Vaccine; 2017 Aug; 35(35 Pt B):4646-4651. PubMed ID: 28711388
[TBL] [Abstract][Full Text] [Related]
13. Impact of 13-valent pneumococcal conjugate vaccine on laboratory-confirmed pneumococcal meningitis and purulent meningitis among children ˂5 years in Cameroon, 2011-2018.
Njuma Libwea J; Fletcher MA; Koki Ndombo P; Boula A; Ashukem NT; Ngo Baleba M; Kingue Bebey RS; Nkolo Mviena EG; Tageube J; Kobela Mbollo M; Koulla-Shiro S; Madhi S; Njanpop-Lafourcade BM; Mohammad A; Begier E; Southern J; Beavon R; Gessner B
PLoS One; 2021; 16(4):e0250010. PubMed ID: 33857235
[TBL] [Abstract][Full Text] [Related]
14. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study.
Waight PA; Andrews NJ; Ladhani SN; Sheppard CL; Slack MP; Miller E
Lancet Infect Dis; 2015 May; 15(5):535-43. PubMed ID: 25801458
[TBL] [Abstract][Full Text] [Related]
15. Clinical and Bacteriological Analysis of Pediatric Pneumococcal Meningitis after 13-Valent Pneumococcal Conjugate Vaccine Introduction in Japan.
Kurihara E; Takeshita K; Tanaka S; Takeuchi N; Ohkusu M; Hishiki H; Ishiwada N
Microbiol Spectr; 2022 Apr; 10(2):e0182221. PubMed ID: 35357224
[TBL] [Abstract][Full Text] [Related]
16. Impact of the pediatric 13-valent pneumococcal conjugate vaccine on serotype distribution and clinical characteristics of pneumococcal pneumonia in adults: The Japan Pneumococcal Vaccine Effectiveness Study (J-PAVE).
Sando E; Suzuki M; Furumoto A; Asoh N; Yaegashi M; Aoshima M; Ishida M; Hamaguchi S; Otsuka Y; Morimoto K
Vaccine; 2019 May; 37(20):2687-2693. PubMed ID: 30975569
[TBL] [Abstract][Full Text] [Related]
17. Pneumococcal serotype distribution among meningitis cases from Togo and Burkina Faso during 2007-2009.
Gessner BD; Sanou O; Drabo A; Tamekloe TA; Yaro S; Tall H; Moïsi JC; Mueller JE; Njanpop-LaFourcade BM
Vaccine; 2012 Dec; 30 Suppl 6():G41-5. PubMed ID: 23228357
[TBL] [Abstract][Full Text] [Related]
18. Persistent Circulation of Vaccine Serotypes and Serotype Replacement After 5 Years of Infant Immunization With 13-Valent Pneumococcal Conjugate Vaccine in the United Kingdom.
Kandasamy R; Voysey M; Collins S; Berbers G; Robinson H; Noel I; Hughes H; Ndimah S; Gould K; Fry N; Sheppard C; Ladhani S; Snape MD; Hinds J; Pollard AJ
J Infect Dis; 2020 Mar; 221(8):1361-1370. PubMed ID: 31004136
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: The indirect cohort design, 2006-2018.
Andrews N; Kent A; Amin-Chowdhury Z; Sheppard C; Fry N; Ramsay M; Ladhani SN
Vaccine; 2019 Jul; 37(32):4491-4498. PubMed ID: 31272872
[TBL] [Abstract][Full Text] [Related]
20. Pneumococcal Conjugate Vaccine Impact on Meningitis and Pneumonia Among Children Aged <5 Years-Zimbabwe, 2010-2016.
Dondo V; Mujuru H; Nathoo K; Jacha V; Tapfumanei O; Chirisa P; Manangazira P; Macharaga J; de Gouveia L; Mwenda JM; Katsande R; Weldegebriel G; Pondo T; Matanock A; Lessa FC
Clin Infect Dis; 2019 Sep; 69(Suppl 2):S72-S80. PubMed ID: 31505631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
